
D2B: Direct-to-Biology Platform
Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and...
Continue Reading
Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and...
Continue Reading
High-throughput screening (HTS) remains a foundational technology in early drug discovery, responsible for identifying approximately one-third of today’s clinical candidates....
Continue Reading
High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...
Continue Reading
Despite major advances in small molecule drug development, most disease-relevant proteins remain beyond the reach of conventional therapeutics. Molecular glues...
Continue Reading
Molecular glues are molecules that can encourage two proteins to interact when they otherwise may not. As a consequence, they...
Continue Reading
Varicella-zoster virus (VZV) is a highly contagious alpha-herpesvirus that infects more than 90% of people worldwide. The primary infection with...
Continue Reading
Cellular senescence plays a crucial role in aging and age-related diseases, making its study essential for the development of new...
Continue Reading
WuXi AppTec offers a comprehensive platform of in silico drug discovery services to accelerate the process of hit finding and...
Continue Reading
The metabotropic glutamate receptor mGluR7 is widely expressed throughout the CNS and has been implicated in numerous CNS disorders. WuXi...
Continue Reading